Edgewise Therapeutics, Inc. Common Stock

Immutrin Ltd, a biotechnology company developing antibody therapy for amyloidosis, has appointed Dr. Robert Blaustein as Chief Medical Officer. Blaustein brings over 15 years of cardiovascular drug development experience from previous roles at Edgewise Therapeutics and Merck. The company has also established a US subsidiary to support planned cli...

Edgewise Therapeutics stock rose 2.18% on Tuesday after JPMorgan analyst Tessa Romero raised her price target by $11 per share to $45, maintaining an overweight rating. The upgrade was driven by optimism about the company's pipeline drugs, particularly EDG-7500 for heart disorder treatment and sevasemten for muscular dystrophy, which showed posit...

Edgewise Therapeutics, a $3.1B biotech company, has two major drug candidates with significant market potential. EDG-7500 for hypertrophic cardiomyopathy uses a novel mechanism (promoting heart relaxation) with superior safety profile compared to existing treatments, with efficacy data expected by June 2026. Sevasemten targets Becker Muscular Dys...

Edgewise Therapeutics stock surged 4% on Monday after analyst Yasmeen Rahimi from Piper Sandler reiterated an overweight recommendation with a $51 price target. Rahimi flagged the biotech as one of Piper Sandler's best stock ideas for 2026, citing strong potential for its lead cardiovascular drug candidate EDG-7500 for treating hypertrophic cardi...

Edgewise Therapeutics stock surged nearly 26% on December 23rd after the biotech presented positive interim Phase 2 clinical trial data for EDG-7500, an investigational drug targeting hypertrophic cardiomyopathy (HCM). The drug showed clinical activity across significant disease markers, maintained a favorable safety profile, and exceeded year-en...